Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
NCT ID: NCT00814255
Last Updated: 2016-07-11
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
32 participants
Study Classification
INTERVENTIONAL
Study Start Date
2008-12-31
Study Completion Date
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This project will test whether adalimumab,and/or galactose can safely reduce proteinuria (abnormal amounts of protein in the urine) and protect kidney function better than standard treatment for patients with focal segmental glomerulosclerosis (FSGS).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)
NCT00193648
Focal Glomerulosclerosis
COMPLETED
PHASE1
Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)
NCT00135811
Glomerulosclerosis, Focal
COMPLETED
PHASE3
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
NCT00464321
Focal Segmental Glomerulosclerosis
COMPLETED
PHASE1
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
NCT04009668
FSGS
MCD
Focal Segmental Glomerulosclerosis
+1 more
COMPLETED
PHASE2
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT01665391
Primary Focal Segmental Glomerulosclerosis
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
SPECIFIC AIMS A significant percentage of patients with primary FSGS are resistant to corticosteroids and other immunosuppressive medications. In view of the rising incidence of this disease and the grim prognosis for patients with resistant disease, it is imperative that new therapeutic approaches be evaluated in an efficient and systematic manner. This will enable accurate assessment of the risk-benefit ratio of novel therapies and guide the design of future Phase III randomized clinical trials.
Specific Aim #1: To evaluate two novel therapies for resistant FSGS -- anti-TNF-α antibody and galactose -- against standard therapy
Specific Aim #2: To identify one or more novel agents as candidates for future study in a Phase III randomized clinical trial
OVERALL STUDY DESIGN Screening/Run-In: There is no formal run-in period in the phase II trial because patients with resistant FSGS who will be eligible for this study often have unstable kidney function and are prone to sudden decline in glomerular filtration rate (GFR). An effort will be made to achieve randomization within 2 weeks of the screening visit.
In order to achieve a comparable baseline assessment prior to initiation of one of the novel therapies, the patients must be off all immunosuppressive medications for 30 days. In addition, patients will be placed on the maximal tolerated doses of an angiotensin-converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB), and a lipid-lowering drug defined above based upon measurements of blood pressure, serum K+, creatinine, and cholesterol concentrations. Patients will have to be on stable doses of the ACEI/ARB treatment for a minimum of 2 weeks prior to randomization into the FONT Phase II study to insure that the initiation of novel therapy does not coincide with a hemodynamically induced change in proteinuria. In order to implement this part of conservative medical therapy, a 2-12 week Screening/Run-In period will precede randomization. Rescreening will be necessary if patients are not randomized to one of the three treatment arms within 12 weeks of the initial screening assessment.
Duration of novel therapy: Novel therapies will be administered for 6 months before assessing efficacy, i.e., \>50% reduction in proteinuria. Although the novel therapies target renal fibrosis, it is anticipated that this period of treatment will be sufficient to document a beneficial effect on proteinuria.
Screening/Run-In: There is no formal run-in period in the phase II trial because patients with resistant FSGS who will be eligible for this study often have unstable kidney function and are prone to sudden decline in GFR. An effort will be made to achieve randomization within 2 weeks of the screening visit.
Frequency of visits: Patients will be evaluated after 0, 2, 8, 16, and 26 weeks of treatment with the novel therapy or conservative medical therapy alone. Thus, there will be a total of 6 visits during the treatment period. A follow-up evaluation will be performed at 1 month, 3 months, and 6 months after discontinuation of the novel therapy, and then every 6 months until the end of the funding period.
Baseline studies
1. Interval History and physical examination
2. Urine protein and creatinine excretion Proteinuria (Up/c) will be expressed as the protein: creatinine ratio (mg: mg) in an early morning specimen.
3. Serum creatinine and calculated GFR, glucose, albumin, pregnancy test
4. A urine, plasma, serum and DNA sample will be collected for storage in the NIDDK FSGS-CT Biorepository. A request will be made to store any residual renal tissue collected for clinical indications during the FONT trial in the NIDDK Biorepository.
Follow-up assessment: Week 2, 8, and 16 Visits
1. Interval history, physical examination, assessment of adverse events
2. First morning urine protein excretion
3. Laboratory analysis as charted below. Urine pregnancy test at 8 and 16 week visit
Final Outcome Visit (Week 26)
1. History and physical examination
2. Morning urine protein and creatinine excretion x 2 (The value will represent the average of two samples collected during the week before the visit.)
3. Serum creatinine and calculated GFR, Serum Na+, K+, HCO3, Cl-, glucose, CPK
4. Blood urea nitrogen (BUN), albumin, cholesterol, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, complete blood count (CBC), antinuclear antibodies (ANA), C3 levels, pregnancy test
5. Urine, serum and plasma for biorepository
6. TSQM patient questionnaire
Preliminary safety, patient tolerance, and pharmacokinetic (PK) data for the two novel therapies, rosiglitazone and adalimumab, that will be used in the Phase II trial were generated through the successful performance of a Phase I study.
In the phase I study, a total of 21 patients were enrolled. 11 were assigned to receive rosiglitazone, and 10 were assigned to receive adalimumab. The patients were evenly divided by gender and pubertal stage. All patients had a GFR \>50 mL/min/1.73 m2.
There were no serious adverse events necessitating the withdrawal of study drug.
Rosiglitazone was stopped in one child due to a questionable allergy. The patients tolerated the experimental medications adequately based on the results of the Treatment Satisfaction Questionnaire for Medication (TSQM) which was administered at week 16.
The PK analyses indicated that the rosiglitazone dose needs to be increased to account for increased clearance and reduced area under the curve in patients with resistant FSGS and nephrotic range proteinuria. For adalumimab, clearance was also enhanced especially after receiving multiple doses. However, these results of the adalimumab PK analyses indicate that no dose adjustment was required.
The PK data for each drug were presented in abstract form at the annual meeting of the American Society of Nephrology and a manuscript summarizing the complete findings in patients treated with rosiglitazone has been submitted for publication.
This Phase II will again rely on the considerable investment of time and resources on the part of the study investigators and the NIH/NIDDK gained through the FSGS-CT (UO1-DK-63455) and the Phase I portion of the FONT study (DK70341). Schneider Children's Hospital (SCH) and University of North Carolina-Chapel Hill (UNC) resources including the GCRCs that were utilized in the R21phase of them study will be available for the R33 portion of the FONT project.
Specific Aim #1: To evaluate two novel therapies for resistant FSGS -- anti-TNF-α antibody and galactose -- against standard therapy
Specific Aim #2: To identify one or more novel agents as candidates for future study in a Phase III randomized clinical trial
OVERALL STUDY DESIGN Screening/Run-In: There is no formal run-in period in the phase II trial because patients with resistant FSGS who will be eligible for this study often have unstable kidney function and are prone to sudden decline in glomerular filtration rate (GFR). An effort will be made to achieve randomization within 2 weeks of the screening visit.
In order to achieve a comparable baseline assessment prior to initiation of one of the novel therapies, the patients must be off all immunosuppressive medications for 30 days. In addition, patients will be placed on the maximal tolerated doses of an angiotensin-converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB), and a lipid-lowering drug defined above based upon measurements of blood pressure, serum K+, creatinine, and cholesterol concentrations. Patients will have to be on stable doses of the ACEI/ARB treatment for a minimum of 2 weeks prior to randomization into the FONT Phase II study to insure that the initiation of novel therapy does not coincide with a hemodynamically induced change in proteinuria. In order to implement this part of conservative medical therapy, a 2-12 week Screening/Run-In period will precede randomization. Rescreening will be necessary if patients are not randomized to one of the three treatment arms within 12 weeks of the initial screening assessment.
Duration of novel therapy: Novel therapies will be administered for 6 months before assessing efficacy, i.e., \>50% reduction in proteinuria. Although the novel therapies target renal fibrosis, it is anticipated that this period of treatment will be sufficient to document a beneficial effect on proteinuria.
Screening/Run-In: There is no formal run-in period in the phase II trial because patients with resistant FSGS who will be eligible for this study often have unstable kidney function and are prone to sudden decline in GFR. An effort will be made to achieve randomization within 2 weeks of the screening visit.
Frequency of visits: Patients will be evaluated after 0, 2, 8, 16, and 26 weeks of treatment with the novel therapy or conservative medical therapy alone. Thus, there will be a total of 6 visits during the treatment period. A follow-up evaluation will be performed at 1 month, 3 months, and 6 months after discontinuation of the novel therapy, and then every 6 months until the end of the funding period.
Baseline studies
1. Interval History and physical examination
2. Urine protein and creatinine excretion Proteinuria (Up/c) will be expressed as the protein: creatinine ratio (mg: mg) in an early morning specimen.
3. Serum creatinine and calculated GFR, glucose, albumin, pregnancy test
4. A urine, plasma, serum and DNA sample will be collected for storage in the NIDDK FSGS-CT Biorepository. A request will be made to store any residual renal tissue collected for clinical indications during the FONT trial in the NIDDK Biorepository.
Follow-up assessment: Week 2, 8, and 16 Visits
1. Interval history, physical examination, assessment of adverse events
2. First morning urine protein excretion
3. Laboratory analysis as charted below. Urine pregnancy test at 8 and 16 week visit
Final Outcome Visit (Week 26)
1. History and physical examination
2. Morning urine protein and creatinine excretion x 2 (The value will represent the average of two samples collected during the week before the visit.)
3. Serum creatinine and calculated GFR, Serum Na+, K+, HCO3, Cl-, glucose, CPK
4. Blood urea nitrogen (BUN), albumin, cholesterol, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, complete blood count (CBC), antinuclear antibodies (ANA), C3 levels, pregnancy test
5. Urine, serum and plasma for biorepository
6. TSQM patient questionnaire
Preliminary safety, patient tolerance, and pharmacokinetic (PK) data for the two novel therapies, rosiglitazone and adalimumab, that will be used in the Phase II trial were generated through the successful performance of a Phase I study.
In the phase I study, a total of 21 patients were enrolled. 11 were assigned to receive rosiglitazone, and 10 were assigned to receive adalimumab. The patients were evenly divided by gender and pubertal stage. All patients had a GFR \>50 mL/min/1.73 m2.
There were no serious adverse events necessitating the withdrawal of study drug.
Rosiglitazone was stopped in one child due to a questionable allergy. The patients tolerated the experimental medications adequately based on the results of the Treatment Satisfaction Questionnaire for Medication (TSQM) which was administered at week 16.
The PK analyses indicated that the rosiglitazone dose needs to be increased to account for increased clearance and reduced area under the curve in patients with resistant FSGS and nephrotic range proteinuria. For adalumimab, clearance was also enhanced especially after receiving multiple doses. However, these results of the adalimumab PK analyses indicate that no dose adjustment was required.
The PK data for each drug were presented in abstract form at the annual meeting of the American Society of Nephrology and a manuscript summarizing the complete findings in patients treated with rosiglitazone has been submitted for publication.
This Phase II will again rely on the considerable investment of time and resources on the part of the study investigators and the NIH/NIDDK gained through the FSGS-CT (UO1-DK-63455) and the Phase I portion of the FONT study (DK70341). Schneider Children's Hospital (SCH) and University of North Carolina-Chapel Hill (UNC) resources including the GCRCs that were utilized in the R21phase of them study will be available for the R33 portion of the FONT project.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Focal Segmental Glomerulosclerosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Conservative medical therapy plus adalimumab
Group Type
EXPERIMENTAL
Adalimumab
Intervention Type
DRUG
Adalimumab 24 mg/m\^2 (maximum dose 40 mg) sc q 14 days
1
Conservative medical therapy (lisinopril, losartan, atorvastatin)
Group Type
ACTIVE_COMPARATOR
Lisinopril, losartan, and atorvastatin
Intervention Type
DRUG
Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
conservative medical therapy plus galactose
drug: galactose 0.2 g /kg/dose (maximum dose 15g) po BID
Group Type
EXPERIMENTAL
galactose
Intervention Type
DRUG
galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adalimumab
Adalimumab 24 mg/m\^2 (maximum dose 40 mg) sc q 14 days
Intervention Type
DRUG
Lisinopril, losartan, and atorvastatin
Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
Intervention Type
DRUG
galactose
galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary FSGS confirmed by renal biopsy OR documentation of a genetic mutation in a podocyte protein associated with the disease
* Failure to respond to prior therapy at least one of the following immunosuppressive medications -- cyclosporine, tacrolimus, mycophenolate mofetil, sirolimus - or other agents prescribed to lower proteinuria
* Age 1-65 years at onset of proteinuria
* Age 1-65 years at time of randomization
* Estimated GFR ≥40 mL/min/1.73 m2 using Schwartz (age \<18 yr) or Cockroft-Gault (age \<18 yr) formula at screening and ≥30 mL/min/1.73 m2 at the end of the Run-In Period and at the time of randomization
* Up/c \> 1.0 g/g creatinine on first morning void
* Steroid resistance defined as failure to achieve sustained Up/c \< 1.0 following a standard course of prednisone/prednisolone/methylprednisolone prescribed for FSGS therapy, OR contraindication/anticipated intolerance to steroid therapy defined as severe obesity, documented decreased bone density, family history of diabetes, or a psychiatric disorder.
* Willingness to follow the protocol, including medications, baseline and follow-up visits, and procedures.
* Failure to respond to prior therapy at least one of the following immunosuppressive medications -- cyclosporine, tacrolimus, mycophenolate mofetil, sirolimus - or other agents prescribed to lower proteinuria
* Age 1-65 years at onset of proteinuria
* Age 1-65 years at time of randomization
* Estimated GFR ≥40 mL/min/1.73 m2 using Schwartz (age \<18 yr) or Cockroft-Gault (age \<18 yr) formula at screening and ≥30 mL/min/1.73 m2 at the end of the Run-In Period and at the time of randomization
* Up/c \> 1.0 g/g creatinine on first morning void
* Steroid resistance defined as failure to achieve sustained Up/c \< 1.0 following a standard course of prednisone/prednisolone/methylprednisolone prescribed for FSGS therapy, OR contraindication/anticipated intolerance to steroid therapy defined as severe obesity, documented decreased bone density, family history of diabetes, or a psychiatric disorder.
* Willingness to follow the protocol, including medications, baseline and follow-up visits, and procedures.
Exclusion Criteria
* Lactation, pregnancy, or refusal of birth control in women of child bearing potential
* Participation in another therapeutic trial involving protocol mandated administration of a immunosuppressive medication concurrently or 30 days prior to randomization
* Active/serious infection (including, but not limited to Hepatitis B or C, HIV)
* History of malignancy
* Abnormality in age appropriate cancer screening in accord with ACS 2003 guidelines (appendix 17.6)
* Patients with uncontrolled blood pressure \> 140/90 or \> 95th percentile for age/height at the end of the run in period
* Diabetes mellitus Type I or II
* Organ transplantation
* Congestive heart failure
* History of prior myocardial infarction
* SLE or multiple sclerosis
* Hepatic disease, defined as serum ALT/AST levels more than 2.5x the upper limit of normal
* Hematocrit \<27%
* Immunosuppressive therapy with cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or rapamycin in the 30 days prior or Rituximab in the 90 days prior to randomization
* Prior treatment with the study medications, rosiglitazone or adalimumab
* Allergy to one of the study medications, i.e., rosiglitazone, adalimumab, lisinopril, losartan or atorvastatin
* Participation in another therapeutic trial involving protocol mandated administration of a immunosuppressive medication concurrently or 30 days prior to randomization
* Active/serious infection (including, but not limited to Hepatitis B or C, HIV)
* History of malignancy
* Abnormality in age appropriate cancer screening in accord with ACS 2003 guidelines (appendix 17.6)
* Patients with uncontrolled blood pressure \> 140/90 or \> 95th percentile for age/height at the end of the run in period
* Diabetes mellitus Type I or II
* Organ transplantation
* Congestive heart failure
* History of prior myocardial infarction
* SLE or multiple sclerosis
* Hepatic disease, defined as serum ALT/AST levels more than 2.5x the upper limit of normal
* Hematocrit \<27%
* Immunosuppressive therapy with cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or rapamycin in the 30 days prior or Rituximab in the 90 days prior to randomization
* Prior treatment with the study medications, rosiglitazone or adalimumab
* Allergy to one of the study medications, i.e., rosiglitazone, adalimumab, lisinopril, losartan or atorvastatin
Minimum Eligible Age
1 Year
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Michigan
OTHER
Sponsor Role
collaborator
The Cleveland Clinic
OTHER
Sponsor Role
collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Sponsor Role
collaborator
NYU Langone Health
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Howard Trachtman, MD
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Medical Center
Debbie Gipson, MD
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Jennifer Gassman, PhD
Role: PRINCIPAL_INVESTIGATOR
The Cleveland Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Miami
Miami, Florida, United States
Site Status
Emory University
Atlanta, Georgia, United States
Site Status
University of Kansas
Kansas City, Kansas, United States
Site Status
Boston Children's Hospital
Boston, Massachusetts, United States
Site Status
University of Michigan
Ann Arbor, Michigan, United States
Site Status
Mayo Clinic
Rochester, Minnesota, United States
Site Status
Children's Mercy Hospital
Kansas City, Missouri, United States
Site Status
Cardinal Glennon Children's Medical Center
St Louis, Missouri, United States
Site Status
Steven and Alexandra Cohen Children's Medical Center of New York
New Hyde Park, New York, United States
Site Status
NYU Langone Medical Center
New York, New York, United States
Site Status
Columbia University Medical Center
New York, New York, United States
Site Status
Carolinas Medical Center
Charlotte, North Carolina, United States
Site Status
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Site Status
Ohio State University
Columbus, Ohio, United States
Site Status
Doernbecher Children's Hospital
Portland, Oregon, United States
Site Status
Medical University of South Carolina
Charleston, South Carolina, United States
Site Status
Texas Tech University
El Paso, Texas, United States
Site Status
University of Alberta
Edmonton, Alberta, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Canada
References
Explore related publications, articles, or registry entries linked to this study.
Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol. 2009 Jan;4(1):39-47. doi: 10.2215/CJN.02310508. Epub 2008 Dec 10.
Reference Type
RESULT
Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT, Savin VJ, Sharma M, Reiser J, Wei C, Somers M, Srivastava T, Gipson DS. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrol. 2015 Jul 22;16:111. doi: 10.1186/s12882-015-0094-5.
Reference Type
RESULT
Liu ID, Willis NS, Craig JC, Hodson EM. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev. 2025 May 8;5(5):CD003594. doi: 10.1002/14651858.CD003594.pub7.
Reference Type
DERIVED
Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3.
Reference Type
DERIVED
Trachtman H, Vento S, Gipson D, Wickman L, Gassman J, Joy M, Savin V, Somers M, Pinsk M, Greene T. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol. 2011 Feb 10;12:8. doi: 10.1186/1471-2369-12-8.
Reference Type
DERIVED
Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis. 2010 Jan;55(1):50-60. doi: 10.1053/j.ajkd.2009.08.019. Epub 2009 Nov 22.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DK70341FII
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
NCT02000440
COMPLETED
PHASE2
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
NCT06664814
RECRUITING
PHASE2
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
NCT02585804
COMPLETED
PHASE4
Permeability Factor in Focal Segmental Glomerulosclerosis
NCT00007475
COMPLETED
PHASE1/PHASE2
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
NCT07213960
NOT_YET_RECRUITING
PHASE2/PHASE3
Rituximab to Prevent Recurrence of Proteinuria
NCT01164098
TERMINATED
PHASE3
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
NCT00782561
TERMINATED
PHASE1
Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
NCT02633046
COMPLETED
PHASE4
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
NCT01155141
COMPLETED
PHASE4
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
NCT03448692
TERMINATED
PHASE2
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
NCT02382874
UNKNOWN
PHASE1
Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
NCT00956059
UNKNOWN
NA
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
NCT04235621
TERMINATED
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
NCT00001959
COMPLETED
PHASE2
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
NCT04950114
TERMINATED
PHASE2
Sirolimus for Focal Segmental Glomerulosclerosis
NCT00040508
COMPLETED
PHASE2
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
NCT03298698
UNKNOWN
PHASE3
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
NCT00883636
TERMINATED
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
NCT05200871
COMPLETED
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
NCT02112838
COMPLETED
PHASE2
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT07268638
RECRUITING
PHASE2
The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis
NCT01451489
TERMINATED
NA
Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
NCT00004990
COMPLETED
PHASE2
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
NCT04065438
RECRUITING
NA
Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
NCT02683889
ACTIVE_NOT_RECRUITING
PHASE3